19-02-2025
Crohn's Disease Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, NDA Approvals, Medication, Pipeline, Epidemiology and Companies by DelveInsight
Crohn's Disease companies working in the treatment market are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (a subsidiary of Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (part of Bristol Myers Squibb), and Eli Lilly and Company.
(Albany, USA) DelveInsight's ' Crohn's Disease Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of Crohn's Disease, historical and forecasted epidemiology as well as the Crohn's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Crohn's Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Crohn's Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Crohn's Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Crohn's Disease market.
Some facts of the Crohn's Disease Market Report are:
The Crohn's disease market size in the 7MM was observed to be USD ~9,000 million in 2023, which is expected to increase by 2034.
Key Crohn's Disease Therapies expected to launch in the market are ENTYVIO (Vedolizumab), STELARA (Ustekinumab), VELSIPITY (etrasimod), Zeposia (Ozanimod; RPC1063), LY-3074828 (mirikizumab), RHB-104, and others.
In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With Moderately to Severely Active Crohn's Disease
In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
In Jan 2025, Eli Lilly and Company announced results of a Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
On October 14, 2024, Eli Lilly and Company reported that more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. The VIVID-1 study is the first Phase 3 trial to report histologic outcomes using a systematic assessment of bowel segments, following ECCO guidelines. These results are being presented at UEG Week in Vienna from October 12-15.
On October 14, 2024, Johnson & Johnson reported positive results for TREMFYA (guselkumab) in Crohn's disease and ulcerative colitis at the United European Gastroenterology (UEG) Week 2024. The data showed high rates of endoscopic remission in biologic-naïve and biologic-refractory patients, including those unresponsive to JAK inhibitors. These findings from the Phase III GALAXI 2 & 3 studies and the QUASAR maintenance study suggest TREMFYA could be a valuable treatment option for patients who have not responded to other biologics.
Leading Crohn's Disease companies working in the market are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others.
On October 14, 2024, Dong-A-ST announced that its Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, received FDA approval for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara, a blockbuster drug developed by Janssen Biotech, generated $10.86 billion in sales globally in 2023, and Imuldosa's approval as a biosimilar offers a more cost-effective alternative for patients requiring long-term therapy for autoimmune conditions.
Crohn's Disease Overview
Crohn's Disease is a chronic inflammatory bowel disease (IBD) that causes inflammation in the gastrointestinal (GI) tract, most commonly affecting the small intestine and colon. This progressive condition leads to symptoms such as abdominal pain, persistent diarrhea, fatigue, weight loss, and malnutrition. The exact cause of Crohn's Disease remains unclear, but it is believed to result from a combination of genetic, environmental, and immune system factors.
The disease presents in different forms, including ileocolitis (affecting the ileum and colon), ileitis (limited to the ileum), gastroduodenal Crohn's Disease (impacting the stomach and duodenum), jejunoileitis (small intestine inflammation), and Crohn's colitis (restricted to the colon). Complications such as strictures, fistulas, abscesses, and bowel obstructions can occur, requiring advanced medical intervention.
Treatment options for Crohn's Disease aim to manage inflammation, alleviate symptoms, and prevent flare-ups. Common therapies include aminosalicylates, corticosteroids, immunomodulators, biologics (such as TNF inhibitors and integrin inhibitors), and JAK inhibitors. In severe cases, surgery may be necessary to remove damaged portions of the intestine. Ongoing research focuses on new targeted therapies, gut microbiome modulation, and personalized treatment approaches to improve long-term outcomes for Crohn's Disease patients.
Learn more about Crohn's Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Crohn's Disease Prevalence
Crohn's Disease Market
The Crohn's disease market is a rapidly evolving segment in the healthcare industry, driven by increasing prevalence, advances in treatment options, and a growing focus on precision medicine. Crohn's disease, a chronic inflammatory bowel disease (IBD), affects the gastrointestinal tract, causing symptoms like abdominal pain, diarrhea, weight loss, and fatigue. Its progressive nature often leads to complications, necessitating long-term management.
The market is dominated by biologics, including tumor necrosis factor (TNF) inhibitors such as infliximab and adalimumab, which remain the cornerstone of treatment. However, emerging therapies like interleukin inhibitors (ustekinumab) and Janus kinase (JAK) inhibitors (upadacitinib) are gaining traction due to improved efficacy and targeted mechanisms of action. Small molecule drugs and biosimilars are further expanding therapeutic options, offering cost-effective solutions.
Key players in the market include AbbVie, Janssen Pharmaceuticals, Takeda, UCB, and Gilead Sciences, among others. The pipeline for Crohn's disease treatments is robust, with several novel agents focusing on enhancing efficacy, safety, and patient convenience.
Regional markets such as North America and Europe lead in revenue due to advanced healthcare infrastructure and higher awareness. The market's future is shaped by increasing patient populations, innovative treatment approaches, and ongoing research into the disease's underlying mechanisms.
Crohn's Disease Epidemiology
The Crohn's Disease epidemiology section provides insights into the historical and current Crohn's Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Crohn's Disease market report also provides the diagnosed patient pool, trends, and assumptions.
Crohn's Disease Drugs Uptake
This section focuses on the uptake rate of the potential Crohn's Disease drugs recently launched in the Crohn's Disease market or expected to be launched in 2020-2034. The analysis covers the Crohn's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Crohn's Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Crohn's Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Crohn's Disease Pipeline Development Activities
The Crohn's Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Crohn's Disease key players involved in developing targeted therapeutics.
Download the report to understand which factors are driving Crohn's Disease market trends @ Crohn's Disease Market Insights
Crohn's Disease Therapeutics Assessment
Major key companies are working proactively in the Crohn's Disease Therapeutics market to develop novel therapies which will drive the Crohn's Disease treatment markets in the upcoming years are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others.
Crohn's Disease Report Key Insights
1. Crohn's Disease Patient Population
2. Crohn's Disease Market Size and Trends
3. Key Cross Competition in the Crohn's Disease Market
4. Crohn's Disease Market Dynamics (Key Drivers and Barriers)
5. Crohn's Disease Market Opportunities
6. Crohn's Disease Therapeutic Approaches
7. Crohn's Disease Pipeline Analysis
8. Crohn's Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Crohn's Disease Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Crohn's Disease Competitive Intelligence Analysis
4. Crohn's Disease Market Overview at a Glance
5. Crohn's Disease Disease Background and Overview
6. Crohn's Disease Patient Journey
7. Crohn's Disease Epidemiology and Patient Population
8. Crohn's Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Crohn's Disease Unmet Needs
10. Key Endpoints of Crohn's Disease Treatment
11. Crohn's Disease Marketed Products
12. Crohn's Disease Emerging Therapies
13. Crohn's Disease Seven Major Market Analysis
14. Attribute Analysis
15. Crohn's Disease Market Outlook (7 major markets)
16. Crohn's Disease Access and Reimbursement Overview
17. KOL Views on the Crohn's Disease Market
18. Crohn's Disease Market Drivers
19. Crohn's Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
· In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With Moderately to Severely Active Crohn's Disease
· In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
· In Jan 2025, Eli Lilly and Company announced results of a Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
